Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management

Li, Panli; Zhang, Aimi; Liu, Ye; Xu, Chunyuan; Tang, Liulin; Ye, Hong; Liu, Qiufang; Wang, Xiuying; Feng, Dagan; Wang, Lisheng; Huang, Gang; Song, Shaoli

doi:10.1089/thy.2017.0570

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RAI uptake in recurrent or metastatic lesions was classified into 4 grades by visual assessment: 0 for no uptake; For faint uptake; For moderate uptake; and For intense uptake. [ 13 ]…”

Section: Methodsmentioning

confidence: 99%

“…Classification of RAI uptake in recurrent or metastatic DTC lesions RAI uptake in recurrent or metastatic lesions was classified into 4 grades by visual assessment: 0 for no uptake; For faint uptake; For moderate uptake; and For intense uptake. [13] SUV max and its ratio of tumor to liver (SUV max /SUV liver , or tumor/liver [T/L]), were calculated to evaluate tumor RAI uptake, respectively, where the term SUV max was defined as the highest value of all the SUV values of true-positive and false negative lesions, whereas SUV liver was defined as the average of the 3 SUV mean values on 3 continuous layers of the liver for a patient.…”

Section: Diagnostic Criteria For Rair-dtcmentioning

confidence: 99%

See 1 more Smart Citation

Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer

et al. 2023

View full text Add to dashboard Cite

In clinical settings, an estimated 10% differentiated thyroid cancer (DTC) cases become radioactive iodide refractory (RAIR), which lack a molecular marker and have fewer treatment selections. A higher uptake of 18F-fluorodeoxyglucose (18F-FDG) might indicate poor prognosis for DTC. This study aimed to evaluate the clinical value of 18F-FDG psitron emission tomography/computed tomography (PET/CT) for the early diagnosis of RAIR-DTC and high-risk DTC. A total of 68 DTC patients were enrolled and underwent 18F-FDG PET/CT for the detection of recurrence and/or metastasis. 18F-FDG uptake was evaluated in patients with different postoperative recurrence risks or TNM stages and compared between RAIR and non-RAIR-DTC based on its maximum standardized uptake value and tumor/liver (T/L) ratio. The final diagnosis was judged by histopathology and follow-up data. Of 68 DTC cases, 42 were RAIR and 24 non-RAIR, with 2 not determined. A total of 263 of 293 lesions detected on 18F-FDG PET/CT were confirmed to be locoregional or metastatic after follow-up. The T/L ratio was significantly higher for RAIR than for non-RAIR (median 5.18 vs 1.44; P < .01) and also significantly higher in postoperative patients at high-risk of recurrence than at low to medium risk (median 4.90 vs 2.16; P < .01). 18F-FDG PET/CT exhibited a sensitivity of 83.3% and specificity of 87.5% for identifying RAIR, with a cutoff T/L value of 2.98. 18F-FDG PET/CT has the potential to diagnose RAIR-DTC early and identify the high-risk DTC. The T/L ratio is a useful parameter for the detection of RAIR-DTC patients.

show abstract

“…RAI uptake in recurrent or metastatic lesions was classified into 4 grades by visual assessment: 0 for no uptake; For faint uptake; For moderate uptake; and For intense uptake. [ 13 ]…”

Section: Methodsmentioning

confidence: 99%

Section: Diagnostic Criteria For Rair-dtcmentioning

confidence: 99%

Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In recent years, the incidence of thyroid cancer has substantially increased worldwide [ 1 , 2 ]. The most common subtype is papillary thyroid carcinoma (PTC), accounting for almost 90% of all thyroid malignancies.…”

Section: Introductionmentioning

confidence: 99%

Integrating US-guided FNAB, BRAFV600E mutation, and clinicopathologic characteristics to predict cervical central lymph-node metastasis in preoperative patients with cN0 papillary thyroid carcinoma

Tian

et al. 2023

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Background The prevalence of cervical central lymph-node metastasis (CLNM) is high in patients with papillary thyroid carcinoma (PTC). There is considerable controversy surrounding the benefits of prophylactic central lymph-node dissection (pCLND) in patients with clinically negative central compartment lymph nodes (cN0). Therefore, it is crucial to accurately predict the likelihood of cervical CLNM before surgery to make informed surgical decisions. Methods Date from 214 PTC patients (cN0) who underwent partial or total thyroidectomy and pCLND at the Guizhou Provincial People's Hospital were collected and retrospectively analyzed. They were divided into two groups in accordance with cervical CLNM or not. Their information, including clinical characteristics, ultrasound (US) features, pathological results of fine-needle aspirations biopsy (FNAB), and other characteristics of the groups, was analyzed and compared using univariate and multivariate logistic regression analyses. Results A total of 214 patients were eligible in this study. Among them, 43.5% (93/214) of PTC patients had cervical CLNM, and 56.5% (121/214) did not. The two groups were compared using a univariate analyses, and there were no significant differences between the two groups in aspect ratio, boundary, morphology, component, and BRAFV600E (P > 0.05), and there were significant differences between gender, age, maximum tumor size, tumor location, capsule contact, microcalcifications, color Doppler flow imaging (CDFI), and Hashimoto's thyroiditis (HT) (P < 0.05). A multivariate logistic regression analysis was performed to further clarify the correlation of these indices. However, only age (OR = 2.455, P = 0.009), maximum tumor size (OR = 2.586, P = 0.010), capsule contact (OR = 3.208, P = 0.001), and CDFI (OR = 2.225, P = 0.022) were independent predictors of cervical CLNM. Combining these four factors, the area under the receiver-operating characteristic (ROC) curve for the joint diagnosis is 0.8160 (95% 0.7596–0.8725). Univariate analysis indicated that capsule contact (P = 0.001) was a possible predictive factor of BRAFV600E mutation. Conclusions In conclusion, four independent predictors of cervical CLNM, including age < 45 years, tumor size > 1.0 cm, capsule contact, and rich blood flow, were screened out. Therefore, a comprehensive assessment of these risk factors should be conducted when designing individualized treatment regimens for PTC patients.

show abstract

Radioiodine based biomedical carriers for cancer theranostics

Guo,

Xiong,

Liu

et al. 2023

Coordination Chemistry Reviews

View full text Add to dashboard Cite

Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management

Cited by 4 publications

References 21 publications

Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer

Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer

Integrating US-guided FNAB, BRAFV600E mutation, and clinicopathologic characteristics to predict cervical central lymph-node metastasis in preoperative patients with cN0 papillary thyroid carcinoma

Radioiodine based biomedical carriers for cancer theranostics

Contact Info

Product

Resources

About